Why does LILRB1 show protective effects against AD while other identified proteins increase risk?

OPEN

The study reveals LILRB1 as protective while BIN1, C1R, SHPS1, and TMEM106B increase AD risk, but provides no mechanistic explanation for this differential effect. This contradiction in protein effects within the same analytical framework requires clarification to understand therapeutic targeting strategies. Gap type: unexplained_observation Source paper: Exploring the Protein-Metabolite Interplay to Discover Novel Drug Targets for Alzheimer's Disease. (2025, The journal of gene medicine, PMID:40974265)

Priority: 0.76 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: Why does LILRB1 show protective effects against AD while other identified proteins increase risk? is a 0.76 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Why does LILRB1 show protective effects against AD while other identified proteins increase risk? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

Resolution

Mechanistic Families

Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (21)

entities-ros→ADentities-histone-methylation→ADentities-atp7b-gene→ADTAU→ADTDP-43→AD

▸ Show 16 more

APOE→ADMIR-146A→ADAD→TAUSOD1→ADSV2A→ADBnip3→ADtau N-terminal fragments→ADAPOE genotype→ADentities-dian-observational-study→ADentities-ltp→ADentities-neprilysin→ADT2D→ADMICROGLIA→ADAGE→ADPARK7→ADSNCA→AD

biomarker for (1)

tau cleavage products→AD

causes (6)

AD→neurodegenerationPHOSPHORYLATED_TAU→ADBETA_AMYLOID→ADAD→IMMUNE_TOLAD→memory_loss

▸ Show 1 more

AD→DEMENTIA

▸ Show 1 more

levetiracetam→AD

treats (1)

HTL9936→AD

🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps

Why does LILRB1 show protective effects against AD while other identified proteins increase risk?

Key Unanswered Questions

Key Researchers

Clinical Trials

Hypothesis Score Distribution

associated with (21)

biomarker for (1)

causes (6)

contributes to (1)

cross disease mechanism in (5)

depleted in (1)

prevents (1)

protective against (1)

regulates (1)

risk factor for (4)

targets (1)

therapeutic target for (6)

treats (1)